Efficacy and Safety of Multi-Session Transcranial Direct Current Stimulation on Social Cognition in Schizophrenia: A Study Protocol for an Open-Label, Single-Arm Trial.

neuromodulation schizophrenia social cognition superior temporal sulcus transcranial direct current stimulation (tDCS)

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
19 Apr 2021
Historique:
received: 30 03 2021
revised: 05 04 2021
accepted: 15 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

Social cognition is defined as the mental operations underlying social behavior. Patients with schizophrenia elicit impairments of social cognition, which is linked to poor real-world functional outcomes. In a previous study, transcranial direct current stimulation (tDCS) improved emotional recognition, a domain of social cognition, in patients with schizophrenia. However, since social cognition was only minimally improved by tDCS when administered on frontal brain areas, investigations on the effect of tDCS on other cortical sites more directly related to social cognition are needed. Therefore, we present a study protocol to determine whether multi-session tDCS on superior temporal sulcus (STS) would improve social cognition deficits of schizophrenia. This is an open-label, single-arm trial, whose objective is to investigate the efficacy and safety of multi-session tDCS over the left STS to improve social cognition in patients with schizophrenia. The primary outcome measure will be the Social Cognition Screening Questionnaire. Neurocognition, functional capacity, and psychotic symptoms will also be evaluated by the Brief Assessment of Cognition in Schizophrenia, UCSD Performance-Based Skills Assessment-Brief, and Positive and Negative Syndrome Scale, respectively. Data will be collected at baseline, and 4 weeks after the end of intervention. If social cognition is improved in patients with schizophrenia by tDCS based on this protocol, we may plan randomized controlled trial.

Sections du résumé

BACKGROUNDS BACKGROUND
Social cognition is defined as the mental operations underlying social behavior. Patients with schizophrenia elicit impairments of social cognition, which is linked to poor real-world functional outcomes. In a previous study, transcranial direct current stimulation (tDCS) improved emotional recognition, a domain of social cognition, in patients with schizophrenia. However, since social cognition was only minimally improved by tDCS when administered on frontal brain areas, investigations on the effect of tDCS on other cortical sites more directly related to social cognition are needed. Therefore, we present a study protocol to determine whether multi-session tDCS on superior temporal sulcus (STS) would improve social cognition deficits of schizophrenia.
METHODS METHODS
This is an open-label, single-arm trial, whose objective is to investigate the efficacy and safety of multi-session tDCS over the left STS to improve social cognition in patients with schizophrenia. The primary outcome measure will be the Social Cognition Screening Questionnaire. Neurocognition, functional capacity, and psychotic symptoms will also be evaluated by the Brief Assessment of Cognition in Schizophrenia, UCSD Performance-Based Skills Assessment-Brief, and Positive and Negative Syndrome Scale, respectively. Data will be collected at baseline, and 4 weeks after the end of intervention. If social cognition is improved in patients with schizophrenia by tDCS based on this protocol, we may plan randomized controlled trial.

Identifiants

pubmed: 33921706
pii: jpm11040317
doi: 10.3390/jpm11040317
pmc: PMC8073289
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Arch Gen Psychiatry. 1991 Jul;48(7):618-24
pubmed: 2069492
Front Hum Neurosci. 2021 Feb 04;15:631838
pubmed: 33613218
Am J Psychiatry. 2003 May;160(5):815-24
pubmed: 12727681
Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):337-49
pubmed: 15133589
Schizophr Res. 2005 Dec 15;80(2-3):213-25
pubmed: 16137859
Br J Psychiatry. 1994 Nov;165(5):640-9
pubmed: 7866679
Psychiatry Clin Neurosci. 2006 Jun;60(3):332-9
pubmed: 16732750
Cognition. 1985 Oct;21(1):37-46
pubmed: 2934210
Front Psychiatry. 2017 Nov 13;8:233
pubmed: 29180969
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7
pubmed: 25601291
Schizophr Bull. 2006 Oct;32 Suppl 1:S44-63
pubmed: 16916889
Schizophr Bull. 2009 May;35(3):493-508
pubmed: 19329559
Neuropsychologia. 2014 Sep;62:202-8
pubmed: 25107678
Lancet. 2004 Jun 19;363(9426):2063-72
pubmed: 15207959
Brain Res Brain Res Rev. 2000 Mar;31(2-3):106-12
pubmed: 10719138
Curr Pharm Des. 2020;26(2):191-200
pubmed: 31840595
Arch Gen Psychiatry. 2002 Feb;59(2):165-72
pubmed: 11825138
Clin EEG Neurosci. 2021 Feb 15;:1550059421991688
pubmed: 33587001
BMJ Open. 2020 Dec 23;10(12):e037654
pubmed: 33361162
Soc Neurosci. 2011;6(5-6):548-58
pubmed: 21943127
Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45
pubmed: 21320389
Front Psychiatry. 2017 Sep 29;8:184
pubmed: 29033856
Schizophr Res. 1995 Sep;17(1):5-13
pubmed: 8541250
Front Psychiatry. 2019 May 15;10:333
pubmed: 31156479
Neuropsychologia. 2003;41(10):1281-9
pubmed: 12757901
Schizophr Bull. 2008 May;34(3):408-11
pubmed: 18375928
Psychiatry Clin Neurosci. 2014 Sep;68(9):701-11
pubmed: 24612235
Clin EEG Neurosci. 2018 Mar;49(2):93-102
pubmed: 28929795
Psychiatry Res. 2006 Dec 1;148(2-3):75-92
pubmed: 17088049
BMC Psychiatry. 2012 Jun 20;12:64
pubmed: 22715980
Curr Biol. 2007 Aug 21;17(16):R724-32
pubmed: 17714666
Schizophr Res. 2020 Feb;216:367-373
pubmed: 31822431
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Schizophr Res. 2008 Oct;105(1-3):165-74
pubmed: 18774263
Schizophr Res. 2015 Jul;165(2-3):171-4
pubmed: 25934168
Psychiatry Res. 1988 Jan;23(1):99-110
pubmed: 3363019
Neuroimage. 2002 Jun;16(2):331-48
pubmed: 12030820
Schizophr Res Cogn. 2014 Oct 12;1(3):137-143
pubmed: 29379746
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1255-60
pubmed: 19625009
J Autism Dev Disord. 2001 Feb;31(1):5-17
pubmed: 11439754

Auteurs

Yuji Yamada (Y)

National Center of Neurology and Psychiatry, Department of Psychiatry, National Center Hospital, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Takuma Inagawa (T)

National Center of Neurology and Psychiatry, Department of Psychiatry, National Center Hospital, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Yuma Yokoi (Y)

National Center of Neurology and Psychiatry, Department of Psychiatry, National Center Hospital, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Aya Shirama (A)

National Center of Neurology and Psychiatry, Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Kazuki Sueyoshi (K)

National Center of Neurology and Psychiatry, Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Ayumu Wada (A)

National Center of Neurology and Psychiatry, Department of Psychiatry, National Center Hospital, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Naotsugu Hirabayashi (N)

National Center of Neurology and Psychiatry, Department of Psychiatry, National Center Hospital, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Hideki Oi (H)

Translational Medical Center, National Center of Neurology and Psychiatry, Department of Clinical Epidemiology, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Tomiki Sumiyoshi (T)

National Center of Neurology and Psychiatry, Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.

Classifications MeSH